Articles tagged with: Myeloma Beacon Forums
News »
Myeloma Experts From University Of Arkansas Answer Questions At The Myeloma Beacon Forums This Week – Dr. Bart Barlogie and Dr. Bijay Nair, myeloma experts from the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences will be answering medical questions posted to the forums at the Myeloma Beacon this week. Readers can post their questions and review answers from other myeloma experts by visiting the Myeloma Beacon Forums.
MMRF Grants Funding To Intellikine and Tragara Pharmaceuticals For Novel Myeloma Treatments – The Multiple Myeloma Research Foundation (MMRF) announced last week that it will award Intellikine and Tragara Pharmaceuticals, two biotech companies based in Southern California, with $1 million each for the development of two new compounds for the treatment of multiple myeloma. Intellikine’s INK128 and Tragara Pharmaceuticals’ TG02 have both shown potential for multiple myeloma in pre-clinical studies. For more information, please see the MMRF press release.
5th Annual “Music Against Myeloma” Fundraiser To Be Held In NYC – On April 22, special musical performances will take place during the 5th annual “Music Against Myeloma” fundraiser to the benefit of the International Myeloma Foundation. The event will take place at BLVD in New York City from 7 to 10 p.m. Advance tickets are $40. Please see the Music Against Myeloma Web site for additional information and to purchase tickets.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News »
Myeloma Experts Continue To Answer Questions At The Myeloma Beacon Forums – The Mayo Clinic, represented by myeloma expert Dr. Martha Lacy, will be answering medical questions posted to the forums at the Myeloma Beacon this week. Readers are encouraged to post their questions to the Myeloma Beacon Forums.
MannKind Receives MMRF Grant For Development Of New Myeloma Treatment – The Multiple Myeloma Research Foundation (MMRF) and MannKind, a biopharmaceutical company based in Valencia, CA, announced today that the MMRF will award MannKind $1 million for the development of a new compound for the treatment of multiple myeloma. The new compound, an IRE-1a inhibitor, inhibits growth of tumor cells, which may in turn make the cancer cells more susceptible to common myeloma treatments. The award is based on results from nonclinical studies. For more information, please see the MannKind press release.
The MMRF Holds Free Myeloma Symposium – On April 9, the Multiple Myeloma Research Foundation (MMRF) will hold a free educational symposium for multiple myeloma patients, their family members and caregivers about the latest advances and treatments in multiple myeloma. The event will take place at the Grand Hyatt in New York, NY from 10 a.m. to 4 p.m. Please see the MMRF Web site to register.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
Headline, News »
The Myeloma Beacon is pleased to announce the launch of an important new service. Starting today, the Beacon Web site will include a range of online discussion forums. These multiple myeloma forums will make it easy for patients, caregivers, and others with an interest in myeloma to meet, share, and discuss myeloma-related information.
The Beacon also is announcing today a major new collaboration that has been arranged in recognition of the significance to the myeloma community of the new Beacon forums.
Over the course of the next month,…
